Gene therapy for neurodegenerative disorders

Abstract

Compositions and methods for treating disorders affecting motor function, such as motor function affected by disease or injury to the brain and/or spinal cord, are disclosed.

1 - 19 . (canceled) 
     
     
         20 : A method of treating spinal muscular atrophy (SMA) in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a pharmaceutical composition comprising a recombinant adeno-associated virus (rAAV) virion to the central nervous system of the subject; wherein the rAAV virion comprises a self-complementary adeno-associated virus (scAAV) vector comprising a polynucleotide encoding a survival motor neuron (SMN) protein, wherein the rAAV virion comprises an AAV9 capsid, wherein the composition is administered via administration into at least one region of the deep cerebellar nuclei of the cerebellum, via direct spinal cord injection, via intracerebroventricular injection, or via intrathecal injection. 
     
     
         21 : The method of  claim 20 , wherein the composition is administered via intracerebroventricular injection into at least one cerebral lateral ventricle. 
     
     
         22 : The method of  claim 20 , wherein the composition is administered via both intracerebroventricular injection and direct spinal cord injection. 
     
     
         23 : The method of  claim 20 , wherein the SMN protein is encoded by human SMN-1. 
     
     
         24 : The method of  claim 20 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2. 
     
     
         25 : The method of  claim 20 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2. 
     
     
         26 : The method of  claim 20 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 
     
     
         27 : The method of  claim 21 , wherein the SMN protein is encoded by human SMN-1. 
     
     
         28 : The method of  claim 21 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2. 
     
     
         29 : The method of  claim 21 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2. 
     
     
         30 : The method of  claim 21 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 
     
     
         31 : The method of  claim 22 , wherein the SMN protein is encoded by human SMN-1. 
     
     
         32 : The method of  claim 22 , wherein the SMN protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2. 
     
     
         33 : The method of  claim 22 , wherein the SMN protein comprises an amino acid sequence of SEQ ID NO:2. 
     
     
         34 : The method of  claim 22 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 
     
     
         35 : The method of  claim 23 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 
     
     
         36 : The method of  claim 24 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. 
     
     
         37 : The method of  claim 25 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient.